TBC1D12: A Potential Drug Target and Biomarker for Inflammatory diseases

Target Name: TBC1D12

NCBI ID: G23232

TBC1D12

Other Name(s): KIAA0608 | TBC12_HUMAN | TBC1 domain family member 12

TBC1D12: A Potential Drug Target and Biomarker for Inflammatory diseases

Inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease (COPD), affect millions of people worldwide and cause significant morbidity and mortality. Chronic inflammation in these diseases can be attributed to the activation and function of various immune cells and their production of pro-inflammatory cytokines. The TBC1D12 gene, located on chromosome 16, has been identified as a key regulator of the immune response and inflammation. This gene has been implicated in the development and progression of several inflammatory diseases, making it a promising drug target and biomarker for the treatment of inflammatory diseases.

The TBC1D12 gene

The TBC1D12 gene is a member of the TBC1 family, which includes several highly conserved genes that are involved in the regulation of cell growth, differentiation, and inflammation. The TBC1D12 gene encodes a protein known as TBC1D12, which is a 21-kDa protein that is expressed in various tissues and cells, including human skeletal muscles, heart, liver, and pancreas.

TBC1D12 functions as a negative regulator of the NF-kappa-B signaling pathway

The NF-kappa-B signaling pathway is a critical pathway involved in inflammation and cellular stress responses. NF-kappa-B signaling is activated in response to various stimuli, including tissue damage, infection, and inflammation, and it plays a role in the regulation of gene expression, cell growth, and differentiation. The TBC1D12 protein has been shown to function as a negative regulator of the NF-kappa-B signaling pathway.

TBC1D12 regulates the activity of NF-kappa-B by controlling the p65尾-catenin complex

The p65尾-catenin complex is a key component of the NF-kappa-B signaling pathway. It consists of the p65尾 subunit of the NF-kappa-B enzyme and the catenin subunit, which interacts with the p65尾 subunit to regulate the activity of the NF-kappa-B pathway. TBC1D12 has been shown to interact with the p65尾 subunit and regulate its activity.

TBC1D12 promotes the formation of the p65尾-catenin complex by interacting with the protein S6

S6 is a protein that is involved in the regulation of DNA binding and cell growth. TBC1D12 has been shown to interact with S6 and promote the formation of the p65尾-catenin complex. This interaction between TBC1D12 and S6 is critical for the regulation of the NF-kappa-B pathway and the development of inflammatory diseases.

TBC1D12 is a potential drug target for inflammatory diseases

The TBC1D12 gene has been shown to be involved in the development and progression of several inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and COPD. In rheumatoid arthritis, TBC1D12 has been shown to be involved in the regulation of immune cell function and the production of pro-inflammatory cytokines. In inflammatory bowel disease, TBC1D12 has been implicated in the regulation of mucosal immune response and the production of pro-inflammatory cytokines. In COPD, TBC1D12 has been shown to be involved in the regulation of airway inflammation and the production of pro-inflammatory cytokines.

In conclusion, the TBC1D12 gene has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases. Further research is needed to understand the full role of TBC1D12 in the development and progression of inflammatory diseases and to develop effective treatments.

Protein Name: TBC1 Domain Family Member 12

Functions: RAB11A-binding protein that plays a role in neurite outgrowth

The "TBC1D12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets